



Protein Aggregation: Molecular Mechanisms, Determinants and Therapeutic Approaches

Guest Editor:

Dr. Nikolaos N. Louros

VIB - KU Leuven, 3000 Leuven,
Belgium

Deadline for manuscript
submissions:

closed (30 November 2022)

Message from the Guest Editor

Macromolecular protein assemblies including protein aggregates, biomolecular condensates, and ordered amyloid fibril formation have been associated with various widespread diseases, spanning from major neurodegenerative disorders to certain forms of cancer. At the same time, amyloid formation has also been shown to support important biological functions starting from humans and extending to single-cell organisms. The recent efflux of structural information on amyloid architecture, combined with studies on the molecular determinants and mechanisms that promote self- and heterotypic assembly, has highlighted certain unresolved properties of protein aggregates, such as structural polymorphism and its differential association to disease, selective vulnerability of specific cell types to certain toxic aggregate species, and complex spreading patterns, while also promoting the design of novel therapeutic approaches against this group of diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)